• Arvinas highlighted FDA clearance of VEPPANU (vepdegestrant) on May 1, 2026 for ER+/HER2-, ESR1-mutated advanced or metastatic breast cancer.
• Global rights to VEPPANU were licensed to Rigel in May 2026, with milestone potential and tiered royalties on net sales.
• Luxdegalutamide was out-licensed to Novartis in 2024, with stated total deal value potential above $1 billion.
• Novartis is running three Phase 2 combination trials for luxdegalutamide across mCRPC and mHSPC settings.
• Arvinas cited more than $800 million in non-dilutive cash from Pfizer and Novartis partnerships, with cash runway into 2H 2028.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Arvinas Inc. published the original content used to generate this news brief on August 07, 2026, and is solely responsible for the information contained therein.